Posted by Michael Wonder on 17 Oct 2023
Diakonos Oncology awarded FDA fast track designation for innovative dendritic cell vaccine for glioblastoma
17 October 2023 - Diakonos Oncology announced today that the US FDA has granted fast track designation for the Company’s unique dendritic cell vaccine, DOC1021.
The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients with glioblastoma multiforme.
